A New Model for Polygenic Risk Assessment in Breast Cancer

EMBER-3 trial data may lead to a new FDA approval while muddying waters for second-line endocrine therapy in ER-positive, HER2-negative advanced breast cancer.

In December, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in skin, breast, and prostate cancer, and more.

New data showing benefit from adding a CDK4/6 inhibitor to endocrine therapy and anti-HER2 therapy in triple-positive advanced breast cancer change practice.

A new song from Moffitt Cancer Center radiologist and musician Dana Ataya, MD, and The ReMissions aims to inspire and empower women about breast cancer.

Data show two paclitaxel regimens had similar outcomes in high-risk, HR-positive, HER2-negative early breast cancer, raising questions about optimal selection.

A phase 3 clinical trial found that neoadjuvant camrelizumab plus chemo improves the rate of pathological complete response in early or locally advanced TNBC.

Key studies in HR-positive, HER2-negative early breast cancer at SABCS 2024 inform practice and “springboard to some additional questions,” says Erin Frances Cobain, MD.

The ZEST trial was designed to guide treatment in breast cancer based on MRD, but was ended when it didn’t accrue enough patients. Results may still offer insights.

Azka Ali, MD, and Robert A. Figlin, MD, discuss advances in HR-positive, HER2-negative metastatic breast cancer care for patients with PIK3CA mutations.

An exploratory biomarker analysis suggests that tumor mutational burden and T-cell–inflamed gene expression may relate to treatment response in early-stage TNBC.

Data from the COMET clinical trial support the safety and efficacy of active monitoring in HR-positive, HER2-negative, low-risk ductal carcinoma in situ.

Trastuzumab deruxtecan outperforms chemo in HR+, HER2-low/ultralow metastatic breast cancer with rapid progression after endocrine therapy, new data show.